Skip to content

Sinus Lift Using PTFE Titanium Reinforced Membrane

Evaluation of Direct Sinus Lift Using Ptfe Titanium Reinfored Membrane Assosiated With Immediate Implant Placement (Clinical Trial)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05044260
Enrollment
12
Registered
2021-09-14
Start date
2020-09-01
Completion date
2021-10-20
Last updated
2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinus Lift

Brief summary

Various attempts have been implemented using different materials and techniques to augment the maxillary sinus floor enhancing autogenous bone formation to allow proper dental implant positioning. The aim of this study is to evaluate the sinus lift procedure using polytetrafluoroethylene (PTFE) titanium-reinforced membrane to maintain the space formed after Schneiderian membrane elevation followed by immediate implant placement.

Interventions

PROCEDUREDirect sinus lift with titanium reinforced PTFE membrane

Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.

Sponsors

Hams Hamed Abdelrahman
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients of both genders requiring implant placement in posterior maxilla * Age range: 40-60 years. * Good oral hygiene * Healthy maxillary sinus free from pathology * The minimum crestal bone height is (4-6) mm * Patients who are willing and fully capable to comply with the study protocol.

Exclusion criteria

* Sinus infection * Tumors or pathologic lesions in sinus * Severe allergic rhinitis. * Chronic topical steroid use. * Radiation therapy. * Psychologic / mental impairment * Acute infection (periodontitis or mucosal infection * Patients on radiotherapy or chemotherapy. * Alcohol or drug abuse. * Patient with systemic disorder (uncontrolled Diabetes mellitus, autoimmune diseases, bone diseases, etc.) * Smokers * Parafuctional habits

Design outcomes

Primary

MeasureTime frameDescription
Change in implant stabilityat baseline and 6 monthsIt will be measured using Osstell
Change in bone formationat baseline and 6 monthsIt will be measured uisng CBCT on Demand 3d software
Change in bone heightat baseline and 6 monthsIt will be measured uisng CBCT on Demand 3d software
Change in bone densityat baseline and 6 monthsIt will be measured uisng CBCT on Demand 3d software

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026